- Home
- BMEA vs GMM Comparison
BMEA vs GMM Comparison
Compare BMEA & GMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- GMM
- Stock Information
- Founded
- BMEA 2017
- GMM 2017
- Country
- BMEA United States
- GMM China
- Employees
- BMEA N/A
- GMM N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- GMM
- Sector
- BMEA Health Care
- GMM
- Exchange
- BMEA Nasdaq
- GMM Nasdaq
- Market Cap
- BMEA 65.8M
- GMM 61.9M
- IPO Year
- BMEA 2021
- GMM 2023
- Fundamental
- Price
- BMEA $1.57
- GMM $2.77
- Analyst Decision
- BMEA Strong Buy
- GMM
- Analyst Count
- BMEA 10
- GMM 0
- Target Price
- BMEA $21.00
- GMM N/A
- AVG Volume (30 Days)
- BMEA 957.5K
- GMM 23.9K
- Earning Date
- BMEA 08-12-2025
- GMM 08-08-2025
- Dividend Yield
- BMEA N/A
- GMM N/A
- EPS Growth
- BMEA N/A
- GMM 62.17
- EPS
- BMEA N/A
- GMM 6.37
- Revenue
- BMEA N/A
- GMM $41,360,953.00
- Revenue This Year
- BMEA N/A
- GMM N/A
- Revenue Next Year
- BMEA N/A
- GMM N/A
- P/E Ratio
- BMEA N/A
- GMM $0.43
- Revenue Growth
- BMEA N/A
- GMM 53.82
- 52 Week Low
- BMEA $1.29
- GMM $1.69
- 52 Week High
- BMEA $13.07
- GMM $15.60
- Technical
- Relative Strength Index (RSI)
- BMEA 37.40
- GMM 53.00
- Support Level
- BMEA $1.72
- GMM $2.53
- Resistance Level
- BMEA $1.75
- GMM $3.09
- Average True Range (ATR)
- BMEA 0.11
- GMM 0.23
- MACD
- BMEA -0.02
- GMM -0.01
- Stochastic Oscillator
- BMEA 9.20
- GMM 49.21
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.